Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Equine tetanus immunoglobulin F(ab′)2 is a purified preparation of F(ab′)2 fragments obtained from the plasma of horses hyperimmunized with tetanus toxoid. It is indicated for the passive immunization and prophylaxis of tetanus in individuals with tetanus-prone wounds, especially when human tetanus immunoglobulin (HTIG) is unavailable. The manufacturing process involves pepsin digestion of equine IgG to remove the Fc portion, which significantly reduces the risk of hypersensitivity reactions and serum sickness compared to traditional whole-molecule equine tetanus antitoxin (TAT). The F(ab′)2 fragments retain the ability to bind and neutralize tetanospasmin, the potent neurotoxin produced by Clostridium tetani, thereby preventing the toxin from binding to gangliosides at the neuromuscular junction and blocking its retrograde axonal transport to the central nervous system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on equine tetanus immunoglobulin F(ab′)2.